comparemela.com
  1. Home
  2. Live Updates
  3. Early Outcomes - Breaking News

Latest Breaking News On - Early outcomes - Page 2 : comparemela.com

Gilead Sciences, Inc : Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:

United statesFoster cityCarol ohearFrank neumannJacquie rossBrexucabtagene autoleucelPivekimab sunirineAxicabtagene ciloleucelCressida robsonMeaghan smithDecitabine cedazuridineSanta monicaGlobal head of clinical developmentGilead sciencesGilead sciences incClinical development

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor. | June 1, 2023

Foster cityUnited statesDecitabine cedazuridineSanta monicaCarol ohearFrank neumannPivekimab sunirineAxicabtagene ciloleucelBrexucabtagene autoleucelDrug administrationExchange commissionGilead companyEuropean hematology associationClinical developmentGilead sciences incGilead sciences

Heart transplants from COVID-19 donors: Mixed outcomes revealed in early analysis

In a recent study published in the Journal of the American College of Cardiology, researchers investigated coronavirus disease 2019 (COVID-19)-infected donor use, donor and recipient characteristics, and early post-heart transplantation (HT) outcomes in the United States (US).

United statesPooja toshniwal pahariaPooja toshniwal pahariamayJournal of the american college cardiologyUnited network for organ sharingPooja toshniwalAmerican collegeEarly outcomesAdult heart transplantation fromImage creditUnited networkOrgan sharingOrgan procurementTransplant networkCovid 19Heart transplantation

Intuitive Surgical (ISRG) Q2 2021 Earnings Call Transcript

Intuitive Surgical (ISRG) Q2 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Intuitive Surgical (NASDAQ: ISRG) Operator Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Q2 2021 earnings conference call. At this time, all participants are in listen-only mode. Later we will have a question-and-answer session. [Operator instructions] As a reminder, this conference is being recorded. And at this time, I would like to turn the conference over to our host, senior director of finance, investor relations for Intuitive, Mr. Calvin Darling. Please go ahead, sir. Calvin Darling

United statesBaton rougeKarl leblancAmerica merrill lynchAmit hazanRick wiseMarshall mohrBob hopkinsGary guthartPhilip kimAmit hazan goldman sachsAsia pacificJamie samathLarry beigelsenLake medical centerGoldman sachs

Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve

Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesKuala lumpurUniversity of texas southwestern medical centerUniversity of cincinnatiLos angelesColl cardiolTomasz mroczekEliane schutteDavid moralesDepartment of pediatrics at university cincinnatiNational cardiology hospital sofia bulgariaUniversity children hospitalNational heart instituteBusiness wireCongenital heart surgeryCincinnati children
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.